Skip to main content
. 2020 May 31;12(6):1421. doi: 10.3390/cancers12061421
AKT Protein kinase-B
Bcl-2 B cell lymphoma-2
BH3 Bcl-2 homology 3
BrdU Bromodeoxyuridine
CA125 Cancer antigen 125
CBD Collagen-binding domains
CCK-8 Cell counting kit 8
CRD Carbohydrate recognition domain
CTLA-4 Cytotoxic T-lymphocyte associated factor-4
Cyt C Cytochrome C
DBF Dibenzofuran
DDR DNA damage response
DFS Disease free survival
EGFR Epidermal growth factor receptor
EMT Epithelial mesenchymal transition
ELISA Enzyme-linked immunosorbent assay
FITC Fluorescein isothiocyanate
Gal-1 Galectin-1
Gal-11 Galectin-11
Gal-13 Galectin-13
Gal-14 Galectin-14
Gal-15 Galectin-15
Gal-2 Galectin-2
Gal-3 Galectin-3
Gal-5 Galectin-5
Gal-7 Galectin-7
Gal-8 Galectin-8
Gal-9 Galectin-9
HIV Human immunodeficiency virus
HGSC High grade serous cancer
IL-17 Interleukin-17
Il-2 Interleukin-2
JNK1 C-jun-NH2-terminal kinase 1
LPS Lipopolysaccharide
MALP2 Macrophage-activating lipopetide-2
MET Mesenchymal epithelial transition
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
MUC1 Mucin 1
MUC5AC Mucin 5AC
MUC6 Mucin 6
MUC16 Mucin 16
NF-IL6 Nuclear factor for interleukin 6
NWGR Aspartate-tryptophan-glycine-arginine
OS Overall survival
PBMC Peripheral blood mononuclear cell
PFS Progression free survival
PI3K Phosphoinositol 3 kinase
shRNA Small hairpin RNA
siRNA Small interfering RNA
TG Thomsen–Friedenreich (TF)
TLR Toll-like receptor
TLR-3 Toll-like receptor-3
TLR-4 Toll-like receptor-4
TMA Tissue microarray
Treg T regulatory